Screener
Cullinan Therapeutics, Inc. CGEM Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
FAQ
- What is Cullinan Therapeutics, Inc.'s total liabilities?
- Cullinan Therapeutics, Inc. (CGEM) reported total liabilities of $42.03M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s total liabilities changed year-over-year?
- Cullinan Therapeutics, Inc.'s total liabilities increased by 49.1% year-over-year, from $28.18M to $42.03M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s total liabilities has grown at a 22.5% compound annual growth rate (CAGR), from $14.39M to $39.64M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Cullinan Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude